ED50 of nefopam in laparoscopic cholecystectomy

The Median Effective Dose of Nefopam for Postoperative Pain Control in Patients Undergoing Laparoscopic Cholecystectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002766

Enrollment

Registered

2018-03-30

Start date

2013-07-08

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Twenty-nine patients were included and scheduled to undergo laparoscopic cholecystectomy. After surgery, pain was evaluated in all patients using a numerical pain scale (NPS). When the patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists physical status of I or II and 20 to 65 ages.

Exclusion criteria

Exclusion criteria: (1) history of convulsions or epilepsy, (2) liver or kidney disease, (3) coronary artery disease, (4) urinary obstructive disease, (5) pregnancy, (6) complications during surgery (intraoperative bleeding, need for adhesiolysis, severe inflammation around gall bladder, etc.), and (7) post-operative pain less than or equal to 3 on a numerical pain scale(NPS)

Design outcomes

Primary

Measure	Time frame
Median effective dose (50% effective dose)	—

Countries

Korea, Republic of

Contacts

Public ContactDong Kyu Lee

Koera University Guro Hospital

entopic@naver.com+82-2-2626-1437

Outcome results